The TAT offensive

Delaney, Martin
March 1993
Advocate;3/9/93, Issue 624, p35
Reports on the decision of the members of the community advisory board at AIDS drug manufacturer Hoffmann-La Roche Inc. to suspend relations with the company. Company's lack of responsiveness to the committee; Slow pace of development of two potentially important AIDS drugs, a TAT inhibitor and a proteinase inhibitor.


Related Articles

  • NEWS IN BRIEF: NEW JERSEY.  // Advocate;3/23/93, Issue 625, p22 

    Reports that about 200 people blocked entrances at the U.S. headquarters of the Swiss pharmaceutical firm Hoffmann-La Roche Inc. in Nutley, New Jersey. Claim that the company was stalling development of a promising AIDS drug until the federal government agrees to subsidize the research.

  • While stocks last... Day, Michael // New Scientist;09/26/98, Vol. 159 Issue 2153, p20 

    Focuses on the donation of drugs for AIDS patients in Africa by Hoffmann-La Roche company. Drugs offered by Hoffman-La Roche; Comments of activists on the donation.

  • New HIV treatment to be distributed through lottery. Snyder, Karyn // Drug Topics;7/10/95, Vol. 139 Issue 13, p40 

    Reports that Hoffman-La Roche has initiated a treatment program that will supply Invirase (saquinavir) to AIDS patients who may benefit from the drug but who are not eligible for ongoing clinical trials. Direct distribution of saquinavir to physicians; Saquinavir as proteinase inhibitor that...

  • BOYCOTT CALLED AGAINST HOFFMANN-LA ROCHE. Delaney, Martin // Advocate;4/9/91, Issue 574, p33 

    Reports that the AIDS Coalition to Unleash Power and other groups have joined in calling for a boycott of Hoffmann-La Roche, manufacturer of the experimental drug ddC.

  • Combo therapy.  // Drug Topics;5/20/96, Vol. 140 Issue 10, p20 

    Reports that Hoffman-La Roche and Abbott are conducting a clinical trial to assess the safety of concurrent therapy with the companies' drugs Invirase and Norvir for treatment of AIDS.

  • Roche lands exclusive rights to market AIDS drug outside US.  // Chemical Market Reporter;1/27/97, Vol. 251 Issue 4, p18 

    Reports on Hoffman-La Roche Inc.'s receiving of exclusive rights to market Viracept, an anti-AIDS drug developed by Agouron Pharmaceuticals Inc.

  • Combination study of Invirase and Norvir starting.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p187 

    Announces the clinical trial to be conducted by Hoffman-La Roche Inc. with Abbott Laboratories on the protease inhibitors Invirase in combination with Norvir and their effectiveness in the treatment of HIV/AIDS. Distinct mutation profile of Invirase.

  • Roche files saquinavir NDA.  // Drug Topics;9/18/95, Vol. 139 Issue 18, p8 

    Reports on Hoffman-LaRoche's submission of a new drug application for Invirase or saquinavir, a protease inhibitor used in the treatment of AIDS.

  • Pharmacy care Kit available from Roche.  // Drug Topics;10/10/94, Vol. 138 Issue 19, p8 

    Reports on the availability of a pharmacy counseling service from Roche Laboratories for patients on Roferon-A therapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics